Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System
International Journal of Dermatology · 2026-04 · 65 (4) · 825-827
DOI: 10.1111/ijd.70082 ↗At a glance
Journal article in International Journal of Dermatology, published online on 2025-09-24. Written by Tung S Tran and 5 co-authors. Institution: Hanoi Medical University, Hanoi, Vietnam. Cited 3 times so far (Crossref); 4 references.
Abstract (original language)
The authors declare no conflicts of interest. Data supporting this study are available upon reasonable request to the corresponding author.
Subjects
Author keywords
Authors and institutions
- Hanoi Medical University, Hanoi, Vietnam.
- National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
- Bassett Medical Center, Cooperstown, New York, USA.
ORCID profiles: Tung S Tran
Cite
APA
Tran, T. S., Le, D. V., Jacobs, J. C., Nguyen, T. M., Wetter, D. A., & Nguyen, G. H. (2026). Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. International Journal of Dermatology, 65(4), 825-827. https://doi.org/10.1111/ijd.70082
Vancouver
Tran TS, Le DV, Jacobs JC, Nguyen TM, Wetter DA, Nguyen GH. Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. International Journal of Dermatology. 2026;65(4):825-827. doi:10.1111/ijd.70082
BibTeX
@article{Tran2026,
author = {Tran, Tung S and Le, Duc V and Jacobs, Jena C and Nguyen, Trang M and Wetter, David A and Nguyen, Giang H},
title = {Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {4},
pages = {825--827},
doi = {10.1111/ijd.70082}
}
EUVIMED